MyMD Pharmaceuticals (MYMD) Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for application no. 16/612,472, entitled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”

The allowed claims cover the new molecular entity Supera-CBD as well as pharmaceutical compositions containing the compound. The USPTO found the claims patentable based in part on the compound’s unexpectedly improved activity and selectivity toward inhibiting cannabinoid receptor type 2 (CB2), a key therapeutic target for neuroinflammatory and neurodegenerative diseases.

“The issuance of this Notice of Allowance for our molecule, Supera-CBD, continues to demonstrate our steadfast commitment to moving forward with and protecting our entire product portfolio," said Adam Kaplin, M.D., Chief Scientific Officer of MyMD. “We are thrilled that Supera-CBD has shown strong promise in treating neuroinflammatory and neurodegenerative diseases, and is expected to be a major focus for our company as we move forward.”

Supera-CBD is a non-toxic, synthetic, preclinical cannabidiol derivative that has been shown in in vitro studies to be approximately 7-8x more effective than plant-derived CBD in inhibiting MAO-A and MAO-B and more than 3x more effective than plant-derived CBD in inhibiting CB2, which should enhance its therapeutic potential to treat pain, inflammation, and neurodegeneration.

Supera-CBD is being developed to address anxiety, chronic pain, and seizures and is on an expected path toward human clinical trials as a proposed therapy for epilepsy, followed by chronic pain.

MyMD has continued to elevate its work in inflammatory diseases and was previously issued US Patent Number 10,835,523 B2, titled “Method of Regulating Tumor Necrosis Factor-Alpha (TNF-α) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation,” which was a significant milestone in the company’s approach toward anti-aging product therapies.

The grant of the ‘472 application will add to the company’s growing worldwide patent portfolio, which includes eleven granted patents pertaining to its lead compound, MYMD-1. These patents, coupled with clinical studies underway, have laid the foundation for the planned Phase 2 trial investigating the use of MYMD-1 in patients with depression due to COVID-19, which was recently announced.

You May Also Be Interested In

• Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Joby Aviation (JOBY) Partners with Abu Dhabi to Establish Electric Air Taxi Ecosystem